[PDF][PDF] Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter …
RE Smith Jr, MS Aapro, H Ludwig, T Pintér… - Journal of Clinical …, 2008 - researchgate.net
RE Smith Jr, MS Aapro, H Ludwig, T Pintér, M Smakal, TE Ciuleanu, L Chen, T Lillie…
Journal of Clinical Oncology, 2008•researchgate.netDarbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving
Chemotherapy or Radiotherapy: Results Page 1 Darbepoetin Alfa for the Treatment of Anemia
in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Robert E. Smith Jr,
Matti S. Aapro, Heinz Ludwig, Tamás Pintér, Martin Šmakal, Tudor E. Ciuleanu, Li Chen, Tom
Lillie, and John A. Glaspy From the South Carolina Oncology Associates, Columbia, SC; Amgen …
Chemotherapy or Radiotherapy: Results Page 1 Darbepoetin Alfa for the Treatment of Anemia
in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Robert E. Smith Jr,
Matti S. Aapro, Heinz Ludwig, Tamás Pintér, Martin Šmakal, Tudor E. Ciuleanu, Li Chen, Tom
Lillie, and John A. Glaspy From the South Carolina Oncology Associates, Columbia, SC; Amgen …
Purpose
The efficacy and safety of darbepoetin alfa (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic chemotherapy or myelosuppressive radiotherapy was evaluated.
researchgate.net